278 related articles for article (PubMed ID: 8217117)
1. Assay of pertussis vaccine reactivity factors by measurement of the paw swelling response, endotoxin and histamine-sensitizing factor.
Vuolo AM; Lustigman B
Biologicals; 1993 Mar; 21(1):45-52. PubMed ID: 8217117
[TBL] [Abstract][Full Text] [Related]
2. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of active pertussis toxin may aid a pertussis vaccine to pass the mouse body weight gain test.
Horiuchi Y; Takahashi M; Asada S; Ishida S
Biologicals; 1994 Sep; 22(3):243-8. PubMed ID: 7811458
[TBL] [Abstract][Full Text] [Related]
4. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
Blumberg DA; Lewis K; Mink CM; Christenson PD; Chatfield P; Cherry JD
Pediatrics; 1993 Jun; 91(6):1158-65. PubMed ID: 8502521
[TBL] [Abstract][Full Text] [Related]
5. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
6. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
7. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines.
Tiru M; Jäätmaa E; Gillenius P; Askelöf P
Dev Biol Stand; 1985; 61():469-75. PubMed ID: 2872128
[TBL] [Abstract][Full Text] [Related]
8. [The development of a new generation of pertussis vaccine].
Chuprinina RP; Bychenko BD; Smirnov VD; Maksiutov RV; Eglit IuKh
Zh Mikrobiol Epidemiol Immunobiol; 1990 Oct; (10):89-94. PubMed ID: 2075771
[TBL] [Abstract][Full Text] [Related]
9. Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.
Marsili I; Pizza M; Giovannoni F; Volpini G; Bartalini M; Olivieri R; Rappuoli R; Nencioni L
Infect Immun; 1992 Mar; 60(3):1150-5. PubMed ID: 1541530
[TBL] [Abstract][Full Text] [Related]
10. The quantitative determination of the paw-swelling activity of pertussis vaccine with special reference to its responsible toxic components.
Ishida S; Iwasa S; Akama K; Asakawa S; Tai M; Kurokawa M
Jpn J Med Sci Biol; 1983 Jun; 36(3):157-70. PubMed ID: 6685199
[TBL] [Abstract][Full Text] [Related]
11. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
12. Murine model for pertussis vaccine encephalopathy: role of the major histocompatibility complex; antibody to albumin and to Bordetella pertussis and pertussis toxin.
Steinman L; Weiss A; Adelman N; Lim M; Oehlert J; Zuniga R; Hewlett E; Falkow S
Dev Biol Stand; 1985; 61():439-46. PubMed ID: 2872126
[TBL] [Abstract][Full Text] [Related]
13. Cell surface antigens of Bordetella pertussis.
Parker CD; Branes LV; Armstrong SK; Frank DW; Cole A
Dev Biol Stand; 1985; 61():123-36. PubMed ID: 2872098
[TBL] [Abstract][Full Text] [Related]
14. Toxicity tests on native and recombinant Bordetella pertussis adenylate cyclase toxin preparations.
Hormozi K; Parton R; Coote J
Dev Biol Stand; 1999; 101():147-54. PubMed ID: 10566788
[TBL] [Abstract][Full Text] [Related]
15. [The immunological basis of the administration of DTP-polio vaccine].
Cohen H
Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants.
Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA; Meschievitz C
Pediatrics; 1993 Apr; 91(4):756-60. PubMed ID: 8464662
[TBL] [Abstract][Full Text] [Related]
17. Dermonecrotic toxin and tracheal cytotoxin, putative virulence factors of Bordetella avium.
Gentry-Weeks CR; Cookson BT; Goldman WE; Rimler RB; Porter SB; Curtiss R
Infect Immun; 1988 Jul; 56(7):1698-707. PubMed ID: 3384473
[TBL] [Abstract][Full Text] [Related]
18. Altered mononuclear phagocyte function in mice treated with the lymphocytosis promoting factor of Bordetella pertussis.
Meade BD; Kind PD; Manclark CR
Dev Biol Stand; 1985; 61():63-74. PubMed ID: 2872133
[TBL] [Abstract][Full Text] [Related]
19. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of reactions associated with pertussis vaccine.
Blumberg DA; Mink CM; Lewis K; Chatfield P; Leach C; Smith LP; Christenson PD; Guravitz L; Steinfeld MB; Marcy SM
Dev Biol Stand; 1991; 73():289-95. PubMed ID: 1778321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
